



Myocardial stunning και regional wall motion abnormalities:  
το κλειδί για την κατανόηση του αιφνίδιου θανάτου  
σε ασθενείς υπό αιμοκάθαρση;

**Βασίλειος Καμπερίδης** MD, MSc, PhD, FESC, FEACVI

Επίκουρος Καθηγητής Καρδιολογίας ΑΠΘ

Α' Καρδιολογική Κλινική ΠΓΝΘ ΑΧΕΠΑ



# Sudden Cardiac Death in Hemodialysis Patients: An In-Depth Review





*Darren Green, MBChB,<sup>1</sup> Paul R. Roberts, MD,<sup>2</sup> David I. New, PhD,<sup>1</sup> and  
Philip A. Kalra, MD<sup>1</sup>*


## Sudden and unexpected death accounts for 1 in 4 deaths in patients with end-stage renal disease (ESRD)

### **Box 2.** Current Indications for ICD Device Therapy in the General Population

Survival of cardiac arrest due to VT or ventricular fibrillation  
Episode of sustained VT causing severe hemodynamic  
compromise  
Episode of sustained VT without hemodynamic compromise +  
EF <35%  
MI + EF <35% + nonsustained VT on 24-h ECG + inducible  
VT on electrophysiologic testing  
MI + EF <30% + QRS duration  $\geq$  120 ms on ECG

## Sudden cardiac death in dialysis patients: different causes and management strategies

Simonetta Genovesi <sup>1,2</sup>, Giuseppe Boriani <sup>3</sup>, Adrian Covic<sup>4,5</sup>, Robin W.M. Vernooij<sup>6,7</sup>, Christian Combe <sup>8,9</sup>, Alexandru Burlacu <sup>5,10</sup>, Andrew Davenport<sup>11</sup>, Mehmet Kanbay<sup>12</sup>, Dimitrios Kirmizis<sup>13</sup>, Daniel Schneditz<sup>14</sup>, Frank van der Sande<sup>15</sup> and Carlo Basile<sup>16,17</sup> on behalf of the EUDIAL Working Group of ERA-EDTA





# Sudden Cardiac Death Among Hemodialysis Patients


Melissa S. Makar, MD,<sup>1,2</sup> and Patrick H. Pun, MD, MHS<sup>1,2</sup>



Α Καρδιολογική Κλινική ΑΧΕΠΑ



**Figure 2.** Rates of sudden cardiac death in (left) selected populations and (right) absolute numbers of affected individuals. Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ND, nondialysis.<sup>16,23</sup>




# Sudden Cardiac Death Among Hemodialysis Patients

Melissa S. Makar, MD,<sup>1,2</sup> and Patrick H. Pun, MD, MHS<sup>1,2</sup>



Α Καρδιολογική Κλινική ΑΧΕΠΑ



**Figure 4.** Major hypothesized risk factors for sudden cardiac death including postulated pathophysiology of sudden cardiac death. Based on information in Di Lullo et al.<sup>78</sup>

# Risk Assessment for Sudden Cardiac Death in Dialysis Patients

Palaniappan Saravanan, MD, MRCP; Neil C. Davidson, MD, FRCP





Α Καρδιολογική Κλινική ΑΧΕΠΑ

**Table 1. Factors Predisposing Dialysis Patients to Ventricular Arrhythmias and SCD**

Factors		
Hemodynamic and biochemical factors	Volume overload	Changes to the substrate
	Electrolyte abnormalities, particularly hyper- and hypokalemia	
	Changes in calcium and phosphate metabolism and hyperparathyroidism	
	Alterations in acid-base balance (blood pH and bicarbonate levels)	
Autonomic and endocrine factors	Anemia	Precipitating factors
	Hypertension	
	Loss of vagal tone due to uremia (uremic autonomic neuropathy)	
	Reduced catabolism of circulating adrenergic hormones	
	Diabetic autonomic neuropathy	
	Activation of renin-angiotensin-aldosterone axis	
	LVH/dilation LVSD	
	Diffuse myocardial fibrosis altering conduction and repolarization	
	Atrial dilation/stretch due to chronic fluid overload	
	Scars of previous myocardial infarctions	
	Rapid fluctuations in volume status and blood pressure around dialysis	
	Fluctuations in electrolytes, particularly potassium, around dialysis	
	Acute coronary ischemia	
	Hypoxia due to sleep apnea	
	Acute changes in autonomic regulation during dialysis	




# Fourth universal definition of myocardial infarction (2018)





# Fourth universal definition of myocardial infarction (2018)



© ESC/ACC/AHA/WHF 2018


**Table 1** Reasons for the elevation of cardiac troponin values because of myocardial injury

<b>Myocardial injury related to acute myocardial ischaemia</b>
Atherosclerotic plaque disruption with thrombosis.
<b>Myocardial injury related to acute myocardial ischaemia because of oxygen supply/demand imbalance</b>
<i>Reduced myocardial perfusion, e.g.</i>
<ul style="list-style-type: none"> <li>• Coronary artery spasm, microvascular dysfunction</li> <li>• Coronary embolism</li> <li>• Coronary artery dissection</li> <li>• Sustained bradyarrhythmia</li> <li>• Hypotension or shock</li> <li>• Respiratory failure</li> <li>• Severe anaemia</li> </ul>
<i>Increased myocardial oxygen demand, e.g.</i>
<ul style="list-style-type: none"> <li>• Sustained tachyarrhythmia</li> <li>• Severe hypertension with or without left ventricular hypertrophy</li> </ul>
<b>Other causes of myocardial injury</b>
<i>Cardiac conditions, e.g.</i>
<ul style="list-style-type: none"> <li>• Heart failure</li> <li>• Myocarditis</li> <li>• Cardiomyopathy (any type)</li> <li>• Takotsubo syndrome</li> <li>• Coronary revascularization procedure</li> <li>• Cardiac procedure other than revascularization</li> <li>• Catheter ablation</li> <li>• Defibrillator shocks</li> <li>• Cardiac contusion</li> </ul>
<i>Systemic conditions, e.g.</i>
<ul style="list-style-type: none"> <li>• Sepsis, infectious disease</li> <li>• Chronic kidney disease</li> <li>• Stroke, subarachnoid haemorrhage</li> <li>• Pulmonary embolism, pulmonary hypertension</li> <li>• Infiltrative diseases, e.g. amyloidosis, sarcoidosis</li> <li>• Chemotherapeutic agents</li> <li>• Critically ill patients</li> <li>• Strenuous exercise</li> </ul>

© ESC/ACC/AHA/WHF 2018



# Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient






**Table 1.** Directions for future investigation and clinical implementation

- 
- Peritoneal dialysis versus HD
  - Antioxidants/anti-inflammatory agents
  - Remote preconditioning
  - HD protocol
    - Dialysate temperature (37°C vs. cooled)
    - Dialysis frequency (daily vs. thrice/week)
    - Volume removed per session (i.e. decreasing ultrafiltration)
    - Session duration of dialysis (long vs. short)
    - Location/vessel of AFV/catheter
    - Central venous catheter versus AVF versus arteriovenous graft
    - Flow rate during HD (lower flow rate vs. higher flow rate)
-



HD

HD





HD

HD




# Speckle Tracking Left Ventricular Global Longitudinal Strain




Baseline : 2-ch  
T1: 0:23




Low : 2-ch  
T1: 2:58



Peak : 2-ch  
T1: 8:11



Baseline : 2-ch  
T1: 0:23



151  
5:22HR



60  
5:42HR

# Myocardial stunning in hemodialysis: What is the overall message?

Smrita DORAJAN,<sup>1,2</sup> Anand CHOCKALINGAM,<sup>1,3</sup> Madhukar MISRA<sup>2</sup>



Α Καρδιολογική Κλινική ΑΧΕΠΑ

## Table 1 Possible mechanisms/contributors of cardiac dysfunction in hemodialysis (HD) patients

---

### Renal replacement predictors

1. Ultrafiltration rate
2. HD-related hypotension
3. Dialysate temperature
4. Rapid HD performed infrequently

### Cardiac predictors

1. Small cardiac chamber size
2. Chamber hypertrophy
3. Epicardial coronary disease with typical ischemia
4. Microvascular endothelial dysfunction
5. Frequent ventricular ectopy and tachycardias

### General medical issues

1. Overmedication with antihypertensive agents
  2. Reduced fluid intake
  3. Volume loss related to sweating, bleeding, etc.
  4. Reduced exercise and muscle tone
-


# Chronic Kidney Disease and Coronary Artery Disease

JACC State-of-the-Art Review



Α Καρδιολογική Κλινική ΑΧΕΠΑ

**CENTRAL ILLUSTRATION** Changes in Cardiovascular Disease Risk During Chronic Kidney Disease Progression




Sarnak, M.J. et al. J Am Coll Cardiol. 2019;74(14):1823-38.

Cardiovascular disease (CVD) event (upper triangle); contributions of atherosclerotic CVD (yellow); nonatherosclerotic CVD (purple), and risk of fatality after CVD event (blue). Reproduced with permission from Wanner et al. (10). CAD = coronary artery disease; LVH = left ventricular hypertrophy.



# Coronary computed tomography angiography in dialysis patients undergoing pre-renal transplantation cardiac risk stratification



Α Καρδιολογική Κλινική ΑΧΕΠΑ



**FIGURE 1** Coronary Plaque Characteristics Identified on Computed Tomography Coronary Angiography




# Prognostic Value of Risk Factors, Calcium Score, Coronary CTA, Myocardial Perfusion Imaging, and Invasive Coronary Angiography in Kidney Transplantation Candidates



Α Καρδιολογική Κλινική ΑΧΕΠΑ

**FIGURE 3** Time-to-Event Analysis



Number of risk factors by (A) major adverse cardiac events (MACE) and (B) mortality. The **green and pink lines** represent patients with <3 versus  $\geq 3$  risk factors, respectively. Coronary artery calcium score group by (C) major adverse cardiac events and (D) mortality. The **green, yellow, and pink lines** represent patients with coronary artery calcium scores of 0, 1 to 399 versus  $\geq 400$ . Number of risk factors combined with coronary artery calcium scores by (E) major adverse cardiac events and (F) mortality. The **green solid and dashed lines** represent patients with <3 risk factors and coronary artery calcium scores <400 versus  $\geq 400$ , respectively. The **pink solid and dashed lines** represent patients with  $\geq 3$  risk factors and coronary artery calcium scores <400 versus  $\geq 400$ , respectively.




## Occurrence of Regional Left Ventricular Dysfunction in Patients Undergoing Standard and Biofeedback Dialysis

Nicholas M. Selby, MD, Stewart H. Lambie, MD, Paolo G. Camici, MD, Christopher S. Baker, MD, and Christopher W. McIntyre, MD

**Table 4. Global (EF) and Regional (SF) LV Function During Standard (HD) and Biofeedback Dialysis**

	EF (%)	SF <sub>(mean)</sub> (%)	SF <sub>(RWMA)</sub> (%)
HD			
Baseline	50.1 ± 10.7	2.64 ± 1.5	2.98 ± 1.7
Peak	48.7 ± 12.3	<b>2.26 ± 1.4*</b>	<b>1.69 ± 1.0†</b>
Recovery	53.4 ± 13.3	2.64 ± 1.3	<b>2.38 ± 1.3††</b>



# Hemodialysis-Induced Cardiac Injury: Determinants and Associated Outcomes



Α Καρδιολογική Κλινική ΑΧΕΠΑ

James O. Burton,\* Helen J. Jefferies,\* Nicholas M. Selby,\* and Christopher W. McIntyre\*<sup>†</sup>

All Patients  
(n = 70)


Patients *with* RWMA  
(n = 45)

Patients *without* RWMA  
(n = 25)


Parameter	Predialysis blood testing		P value
	Patients <i>with</i> RWMA	Patients <i>without</i> RWMA	
Haemoglobin (g/dl)	11 ± 1.3	11.5 ± 1	0.15
Haematocrit (%)	36 ± 4	36 ± 2	0.35
Na <sup>+</sup> (mEq/L)	138 ± 3	139 ± 4	0.18
K <sup>+</sup> (mEq/L)	4.8 ± 0.8	4.7 ± 0.9	0.89
Urea nitrogen (mg/dl)	59.1 ± 15.1	55.5 ± 14.0	0.33
Creatinine (mg/dl)	8.8 ± 2.5	9.8 ± 2.9	0.13
Phosphorus (mg/dl)	5.3 ± 1.2	5.0 ± 1.9	0.42
Bicarbonate (mEq/L)	22.7 ± 3.0	22.8 ± 3.2	0.87
Calcium (mg/dl)	9.68 ± 0.6	9.6 ± 0.6	0.58
Albumin (g/dl)	3.5 ± 0.4	3.7 ± 0.3	0.02
hsCRP (mg/L)	1.2 ± 1.0	0.8 ± 0.7	0.13
cTnT (ng/ml)	0.098 ± 0.08	0.036 ± 0.04	0.001

Table 3. The effect of increasing ultrafiltration (UF) volume and worsening intradialytic haemodynamics on the development of HD-induced RWMA

Factor associated with presence of myocardial stunning	Odds Ratio	P value
UF volume during HD of 1L	5.1	0.007
UF volume during HD of 1.5L	11.6	
UF volume during HD of 2L	26.2	
Maximum SBP reduction during HD of 10 mmHg	1.8	0.002
Maximum SBP reduction during HD of 20 mmHg	3.3	
Maximum SBP reduction during HD of 30 mmHg	6.0	



▲ Patients *with* evidence of HD-induced RWMA\*  
■ Patients *without* evidence of HD-induced RWMA<sup>†</sup>



# Hemodialysis-Induced Cardiac Dysfunction Is Associated with an Acute Reduction in Global and Segmental Myocardial Blood Flow

Christopher W. McIntyre,<sup>\*†</sup> James O. Burton,<sup>\*</sup> Nicholas M. Selby,<sup>\*</sup> Lucia Leccisotti,<sup>‡</sup> Shvan Korsheed,<sup>\*</sup> Christopher S.R. Baker,<sup>‡</sup> and Paolo G. Camici<sup>‡</sup>

## PET and ECHO




Figure 1. Mean global myocardial blood flow (MBF) reduced significantly during dialysis from baseline with partial restoration in the recovery period.





Figure 3. The development of regional ventricular dysfunction as measured by regional wall motion abnormalities (RWMA; abnormal regions) was associated with a greater reduction in MBF from baseline than areas that maintained normal movement (normal regions;  $P = 0.001$ ).






Figure 4. An MBF reduction of  $\geq 30\%$  was associated with a mean reduction in wall motion of  $-15.2\%$ ; however, an MBF reduction of  $< 30\%$  was associated with a mean increase in wall motion of  $5\%$  ( $P < 0.01$ ).



# Haemodialysis is associated with a pronounced fall in myocardial perfusion

Judith J. Dasselaar<sup>1,2</sup>, Riemer H. J. A. Slart<sup>3</sup>, Martine Knip<sup>2</sup>, Jan Pruijm<sup>3</sup>, René A. Tio<sup>4</sup>, Christopher W. McIntyre<sup>5</sup>, Paul E. de Jong<sup>2</sup> and Casper F. M. Franssen<sup>1,2</sup>



**Fig. 3.** Relationship between the relative change in myocardial blood flow and the relative change in cardiac output (both from baseline). The open squares represent the correlation at 30 min of HD (not significant). The closed squares represent the correlation at 220 min of HD ( $r = 0.84$ ;  $P = 0.03$ ).

# Association of segmental wall motion abnormalities occurring during hemodialysis with post-dialysis fatigue

**Table 2. Adjusted relative risk for severe PDF**

	Model 1			Model 2		
	RR	(95% CI)	P-value	RR	(95% CI)	P-value
Change in the wall motion abnormality score (point)	1.2	(1.1, 1.3)	<0.001	1.9	(1.4, 2.6)	<0.001
Depression	3.4	(1.3, 9.0)	0.01	2.0	(0.6, 6.8)	0.3
Decrease in SBP during dialysis (mmHg) <sup>a,b</sup>	—	—	—	1.6	(0.8, 3.1)	0.15
Increase in SBP during dialysis (mmHg) <sup>a,b</sup>	—	—	—	1.1	(0.6, 2.2)	0.7
Ultrafiltration (L) <sup>b</sup>	—	—	—	1.0	(0.7, 1.4)	0.9

**Table 1. Cohort characteristics and univariate relative risks for PDF**


	Absent or mild fatigue <sup>a</sup> (n = 32)	Severe fatigue <sup>a</sup> (n = 8)	Univariate relative risk for severe PDF		
			RR	95% CI	P-value
<b>Demographics</b>					
Age (years)	61 (±15)	61 (±15)	0.99	(0.97, 1.0)	0.9
Dialysis vintage (years)	5 (±6)	3.3 (±2)	0.92	(0.8, 1.0)	0.16
Male gender	25 (78%)	8 (100%)	1.3	(0.4, 5.1)	0.7
Caucasian race	6 (19%)	3 (38%)	2.5	(0.95, 6.6)	0.06
<b>Clinical factors</b>					
History of depression	5 (18%)	3 (30%)	4.6	(1.8, 12)	0.002
Diabetes	15 (47%)	3 (38%)	0.6	(0.2, 1.9)	0.4
Atherosclerosis <sup>b</sup>	14 (44%)	4 (50%)	1.6	(0.5, 4.7)	0.4
Myocardial infarction	8 (26%)	1 (13%)	0.7	(0.2, 1.9)	0.4
Congestive heart failure	6 (19%)	0 (0%)	0.3	(0.05, 1.4)	0.1
Pre-dialysis SBP (mmHg) <sup>c,d</sup>	140 (±18)	143 (±7)	1.1	(0.9, 1.5)	0.4
Hemoglobin (g/dL)	11 (±1)	11 (±2)	0.9	(0.6, 1.2)	0.4
Albumin (g/dL)	3.7 (±0.4)	3.6 (±0.5)	0.6	(0.2, 1.3)	0.19
Phosphorus (mg/dL)	5.3 (±2)	5.6 (±1)	1.1	(0.9, 1.4)	0.5
Parathyroid hormone (mg/dL)	286 (7, 2800)	331 (97, 2800)	1.0	(0.99, 1.0)	0.4
<b>Dialysis-related factors</b>					
Symptomatic hypotension <sup>e</sup>	6 (19%)	2 (25%)	1.5	(0.7, 3.6)	0.3
Decrease in SBP during dialysis (mmHg) <sup>c,d</sup>	25 (±15)	32 (±8)	1.3	(0.96, 1.8)	0.09
Increase in SBP during dialysis (mmHg) <sup>c,d</sup>	13 (±9)	9 (±5)	0.5	(0.3, 1.1)	0.1
Ultrafiltration <sup>c</sup> (l)	2.5 (±1)	3 (±1)	1.4	(0.9, 2.1)	0.19
Kt/v	1.6 (±0.3)	1.6 (±0.3)	0.8	(0.18, 3.4)	0.8
<b>Echocardiographic factors</b>					
Left ventricular mass index (g/m <sup>2</sup> )	99 (59, 172)	87 (61, 170)	0.3	(0.07, 1.3)	0.1
Baseline abnormal diastolic function	22 (69%)	5 (63%)	0.7	(0.3, 1.5)	0.4
Baseline ejection fraction <sup>d</sup>	57% (±7%)	56% (±5%)	<0.001	(<0.001, >1000)	0.5
Baseline WMA	8 (25%)	2 (25%)	0.6	(0.13, 2.4)	0.4
Worsened WMA (dichotomous)	5 (16%)	4 (50%)	1.7	(1.1, 1.9)	0.04
Average change in the WMA score (point)	0 (−1.5, 2.7)	0 (0, 8)	1.1	(1.1, 1.2)	<0.001




## Echocardiography in Hemodialysis Patients: Uses and Challenges

Diana Y.Y. Chiu, MBChB,<sup>1,2</sup> Darren Green, PhD,<sup>1,2</sup> Nik Abidin, MBBS,<sup>3</sup> Smeeta Sinha, PhD,<sup>1,2</sup> and Philip A. Kalra, MD<sup>1,2</sup>

AJKD





**Figure 4.** Schematic representation of the 3 components of left ventricular (LV) contraction. From the end-diastolic position of maximum volume (A), the ventricle will shorten longitudinally from the base to the apex (B to C), undergo torsion/twisting around its longitudinal axis (D) and radial strain that causes a thickening of the myocardial wall and a narrowing of the perpendicular radius (E to F). The resultant change in LV cavity volume (A to G) represents ejection fraction. Reproduced from Green et al<sup>10</sup> with permission of Oxford University Press.



# Left Ventricular Systolic Strain in Chronic Kidney Disease and Hemodialysis Patients

Yen-Wen Liu<sup>a,b</sup> Chi-Ting Su<sup>c</sup> Yao-Yi Huang<sup>b</sup> Chun-Shin Yang<sup>e</sup>  
 Jenq-Wen Huang<sup>d</sup> Mao-Ting Yang<sup>e</sup> Jyh-Hong Chen<sup>a</sup> Wei-Chuan Tsai<sup>a</sup>



**Fig. 3.** Using linear regression analysis, left ventricular GS decreased significantly with deteriorating renal function (eGFR) in the controls and the moderate-advanced CKD group.

# Acute Stunning Effect of Hemodialysis on Myocardial Performance: a Three Dimensional Speckle



Α Καρδιολογική Κλινική ΑΧΕΠΑ

## Tracking Echocardiographic Study

Table-2. Left ventricle analysis before and after HD.

Left ventricle (LV) (n:38)	Pre-hemodialysis	Post-hemodialysis	p value
End diastolic volume index (EDVi) (ml/m <sup>2</sup> )	69 ± 23	57 ± 23	<0.001
End systolic volume index (ESVi) (ml/m <sup>2</sup> )	32 ± 18	28 ± 16	0.010
Stroke volume index (SVi) (ml/m <sup>2</sup> )	37 ± 10	28 ± 10	<0.001
LV mass index (LVMI) (g/m <sup>2</sup> )	72 ± 10	68 ± 8	0.022
Ejection fraction (EF) (%)	55 ± 9	52 ± 9	0.001
Cardiac output (CO) (lt/min)	4.9 ± 1.6	3.9 ± 1.4	<0.001
Global longitudinal strain (GLS) (%)	-14.2 ± 5.2	-11.1 ± 4.6	<0.001
Global circumferential strain (GCS) (%)	-14.8 ± 4.2	-12.4 ± 5.2	0.009
Global radial strain (GRS) (%)	41.5 ± 16	33.3 ± 16.5	0.003
Global area strain (GAS) (%)	-24.7 ± 7.2	-20.1 ± 7.6	0.001
TWIST (degree)	4.7 ± 4.2	5.6 ± 4.9	0.413
TORSION (degree/cm)	0.87 ± 0.61	1.25 ± 1.34	0.285

p < 0,05

Table-6. The effect of beta blocker treatment on strain parameters before and after HD.

	Beta Blocker					
	Before	After	p	Before	After	p
	User (n:19)			Non user (n:19)		
GLS (%)	-12.9 ± 5.3	-11.9 ± 5.1	0.243	-15.5 ± 5.1	-10.3 ± 4.1	<0.001
GCS (%)	-14.1 ± 4.4	-14.1 ± 5.8	0.953	-15.4 ± 4	-10.9 ± 4.2	0.001
GRS (%)	38.3 ± 16.4	37.9 ± 19.4	0.909	44.5 ± 15.6	29.1 ± 12.6	<0.001
AREA (%)	-23 ± 7.6	-22.3 ± 8.4	0.683	-26.3 ± 6.6	-18.1 ± 6.5	<0.001

Table-4. Relationship between changes in strain parameters and blood pressure.

Left ventricle	Systolic tension		Diastolic tension		Pulse	
	r	p	r	p	r	p
GLS	0.527	0.002	0.435	0.015	0.368	0.042
GCS	0.410	0.022	0.310	0.089	0.287	0.117
GRS	0.411	0.022	0.411	0.022	0.380	0.035
AREA	0.446	0.012	0.385	0.032	0.425	0.017

Table-7. The effect of calcium channel blocker treatment on strain parameters before and after HD.


	Calcium channel blocker					
	Before	After	p	Before	After	p
	User (n:18)			Non user (n:20)		
GLS (%)	-14 (-18, -4)	-11 (-18, -3)	0.090	-16.2 ± 5.1	-10.8 ± 5.1	<0.001
GCS (%)	-13.7 ± 4	-13 ± 5.6	0.536	-15.9 ± 4.2	-11.9 ± 5	0.006
GRS (%)	35.5 ± 13.6	34.8 ± 15.4	0.763	52.5 (21, 68)	27.5 (10, 80)	0.002
AREA (%)	-22 ± 6.8	-21.2 ± 7.7	0.565	-30 (-35, -16)	-18 (-33, -8)	0.001






# The Impact of Hemodialysis on Segmental and Global Longitudinal Myocardial Strain

Shih-Han S. Huang, MD,<sup>a,b,c</sup> Lisa E. Crowley, MD,<sup>a</sup> Helen J. Jefferies, MD,<sup>a</sup>  
 Mohamad T. Eldehni, MD,<sup>a</sup> Aghogho Odudu, MD,<sup>a</sup> and Chris W. McIntyre, MD<sup>a,b</sup>



**Table 1.** The segmental longitudinal strain values: before dialysis and at peak dialysis

Segment	Before dialysis		Peak dialysis		P
	Mean (%)	SD	Mean (%)	SD	
Basal inferior	-10.1	7.46	-9.8	7.66	0.73
Midinferior	-14.7	6.64	-13.7	7.14	0.20
Apical inferior	-16.7	8.23	-15.3	8.69	0.10
Apical anterior	-10.3	8.95	-10.0	8.67	0.77
Midanterior	-8.3	7.15	-6.8	7.27	0.10
Basal anterior	-8.2	7.86	-6.4	7.69	0.06
Basal septal	-9.4	6.59	-8.3	6.80	0.18
Midseptal	-13.7	6.23	-12.5	6.20	0.13
Apical septal	-15.16	8.64	-13.7	8.55	0.09
Apical lateral	-10.1	10.03	-10.0	8.78	0.96
Midlateral	-9.6	8.25	-8.3	7.56	0.14
Basal lateral	-9.3	8.13	-6.8	7.13	0.01



No. of Patients at risk	0	1	2	3	4	5
< 80% of segments	19	16	13	13	11	7
≥ 80% of segments	85	68	49	32	20	11

**Figure 3.** Kaplan-Meier Analysis comparing survival time between the groups that had > 80% of segments above the mean segmental longitudinal strain, and ≤ 80% of segments above the mean segmental longitudinal strain.

# Estimated left ventricular pressure-myocardial strain loop as an index of cardiac work predicts all-cause mortality in patients receiving regular hemodialysis

Ke-Wei Chen <sup>a,b</sup>, Wen-Tsong Hsieh <sup>c</sup>, Chih-Yang Huang <sup>d,e,f</sup>, Chih-Chia Huang <sup>a</sup>, Hsin-Yueh Liang <sup>b,g,\*</sup>, Guei-Jane Wang <sup>a,d,e,h,\*\*</sup>

K.-W. Chen, W.-T. Hsieh, C.-Y. Huang et al.

Journal of Diabetes and its Complications 35 (2021) 107890

**Table 2**

Univariate and multivariable Cox regression analyses of all-cause mortality.

	Univariate Cox analysis		Multivariate Cox analysis			
	HR (95% CI)	p value	Model 1		Model 2	
			HR (95% CI)	p value	HR (95% CI)	p value
Age (≥70 yrs)	3.28 (1.61–6.69)	0.001	2.91 (1.40–6.07)	0.004	2.66 (1.29–5.49)	0.008
CWI (<1271 mmHg%)	5.11 (2.40–10.91)	<0.001	2.97 (1.26–7.01)	0.013	4.30 (2.00–9.25)	<0.001
GLS (>−18.15%)	2.82 (1.26–6.34)	0.012	1.82 (0.71–4.65)	0.211		

Abbreviations: CWI = cardiac work index. GLS = global longitudinal strain. HR = hazard ratio. 95% CI = 95% confidence interval. ROC = receiver operating characteristic. The cut-off values of CWI and GLS were determined by ROC curve analysis with optimal sensitivity and specificity.




Fig. 2. The prediction potential of left ventricular ejection fraction (LVEF), global longitudinal strain (GLS) and cardiac work index (CWI) on prognosis of end-stage kidney disease (ESRD) patients receiving regular hemodialysis. (a) LVEF; (b) GLS; (c) CWI used to predict all-cause mortality. (d) Comparison of CWI from survival (orange) vs. mortality (grey) groups. The CWI of these two cases are close to mean values of survival and mortality groups, respectively (1880.86%-mmHg vs. 1377.51%-mmHg).




Fig. 4. All-cause mortality dichotomized according to GLS (≤−18.15 and >−18.15) and CWI (≤1271 mmHg-% and >1271 mmHg-%).

# The impact of volume overload on right heart function in end-stage renal disease patients on hemodialysis

Serkan Ünlü MD, MSc<sup>1,2,3</sup>  | Asife Şahinarslan MD<sup>1</sup> | Gökhan Gökalp MD<sup>1</sup> | Özden Seçkin MD<sup>1</sup> | Selim Turgay Arınsoy MD<sup>4</sup> | Nuri Bülent Boyacı MD<sup>1</sup> | Atiye Çengel MD<sup>1</sup>

**TABLE 4** 2D speckle tracking strain measurements of right ventricle and right atrium before and after hemodialysis

Parameters	Before HD	After HD	P
Right ventricle			
RV GLS (%)	-24.1 ± 3.7	-19.9 ± 4.2	<.001
RV SR (s <sup>-1</sup> )	-1.3 ± 0.3	-1.2 ± 0.3	.084
RV early diastolic SR (s <sup>-1</sup> )	1.3 ± 0.4	1.1 ± 0.4	<.001
RV late diastolic SR (s <sup>-1</sup> )	1.1 ± 0.5	1.1 ± 0.4	.941
RVFW LS (%)	-28.8 ± 4.7	-23.7 ± 5.5	<.001
RVFW SR (s <sup>-1</sup> )	-1.8 ± 0.4	-1.7 ± 0.4	.089
RVFW early diastolic SR (s <sup>-1</sup> )	1.8 ± 0.5	1.4 ± 0.6	<.001
RVFW late diastolic SR (s <sup>-1</sup> )	1.5 ± 0.6	1.5 ± 0.6	.928
Right atrium			
RA reservoir LS (%)	45.6 ± 10.8	38.2 ± 8.1	<.001
RA contraction LS (%)	-16.7 ± 6.8	-16.4 ± 7.1	.835
RA reservoir SR (s <sup>-1</sup> )	2.3 ± 0.7	2.5 ± 0.5	.090
RA conduit phase SR (s <sup>-1</sup> )	-1.5 ± 0.8	-1.2 ± 0.6	<.001
RA contraction SR (s <sup>-1</sup> )	-2.2 ± 0.9	-2.2 ± 0.7	.596

The high ultrafiltration volumes are shown to be associated with myocardial stunning.

**TABLE 3** Conventional echocardiographic measurements before and after hemodialysis

Parameters	Before HD	After HD	P
Dimensions, areas, and volumes of right heart chambers			
RV basal diameter (cm)	3.4 ± 0.6	2.7 ± 0.5	<.001
RV mid-cavity diameter (cm)	2.1 ± 0.5	1.8 ± 0.4	<.001
RV longitudinal diameter (cm)	6.4 ± 0.8	5.8 ± 0.8	<.001
RA longitudinal axis (cm)	4.7 ± 0.6	4.5 ± 0.5	<.001
RA short axis (cm)	3.5 ± 0.6	3.0 ± 0.5	<.001
RA end-systolic area (cm <sup>2</sup> )	13.8 ± 3.0	10.6 ± 2.8	<.001
RV diastolic area (cm <sup>2</sup> )	13.7 ± 3.0	10.1 ± 2.8	<.001
RV end-systolic area (cm <sup>2</sup> )	7.05 ± 2.0	5.9 ± 3.0	<.001
RV FAC (%)	48.3 ± 9.8	46.9 ± 9.2	.389
TAPSE (cm)	2.1 ± 0.4	1.7 ± 0.3	<.001
Doppler measurements of right ventricle			
E (cm/s)	71 ± 23	50 ± 15	<.001
A (cm/s)	58 ± 17	48 ± 16	<.001
E/A	1.3 ± 0.5	1.1 ± 0.3	.004
MPI	0.3 ± 0.2	0.5 ± 0.2	<.001
sPAP	43 ± 17	25 ± 12	<.001
Deceleration time (ms)	219.5 ± 77.8	250 ± 96.4	.032
Tissue Doppler measurements of right ventricle			
E' (cm/s)	14 ± 3	10 ± 3.0	<.001
A' (cm/s)	16.0 ± 4.0	15.0 ± 4.0	.147
E'/A'	0.9 ± 0.4	0.7 ± 0.3	<.001
S' (cm/s)	15.0 ± 3.0	12.0 ± 3.0	<.001
E/E'	5.4 ± 2.3	5.5 ± 2.1	.648
MPI	0.5 ± 0.1	0.6 ± 0.2	.002
IVA (m/s <sup>2</sup> )	35.4 ± 11.7	37.9 ± 14.1	.066

## Echocardiography in Hemodialysis Patients: Uses and Challenges

Diana Y.Y. Chiu, MBChB,<sup>1,2</sup> Darren Green, PhD,<sup>1,2</sup> Nik Abidin, MBBS,<sup>3</sup>  
Smeeta Sinha, PhD,<sup>1,2</sup> and Philip A. Kalra, MD<sup>1,2</sup>




### Box 1. Causes of an Enlarged Left Atrium in Hemodialysis Patients

#### Increased preload to left atrium

- Volume overload
- Mitral valve regurgitation
- Arteriovenous fistula
- High-output states: chronic anemia


#### Increased afterload to left atrium

- Left ventricular systolic dysfunction
- Mitral stenosis
- Hypertension
- Left ventricular hypertrophy




**Figure 1.** Classification of left ventricular (LV) geometry. Note: Relative wall thickness (RWT) is calculated from echocardiographic parameters by  $(2 \times \text{posterior wall thickness}) / \text{Left ventricular diastolic diameter}$  or  $\text{septal wall thickness} + (\text{posterior wall thickness} / \text{Left ventricular diastolic diameter})$ . Because LV mass end-diastolic volume (M/V) is directly proportional to RWT (RWT of 0.32-0.42 corresponds to M/V of 1.0-1.5), RWT may be replaced by M/V whereby an enlarged M/V with increased LV mass index is classified as concentric hypertrophy. In concentric remodeling and hypertrophy, end-diastolic volume is reduced, whereas in eccentric hypertrophy, end-diastolic volume is enlarged. Abbreviation: LVMI, left ventricular mass index. Figure reproduced from Gerds<sup>15</sup> with permission of Oxford Uni-

# LV Diastolic Dysfunction



## CENTRAL ILLUSTRATION: Algorithm for Combining Left Atrial Reservoir Strain With Existing Diastolic Parameters



Potter, E.L. et al. J Am Coll Cardiol Img. 2020;13(11):2316-26.

# The Ebb and Flow of Echocardiographic Cardiac Function Parameters in Relationship to Hemodialysis Treatment in Patients with ESRD




Α Καρδιολογική Κλινική ΑΧΕΠΑ

Charalampos Loutradis,<sup>1</sup> Pantelis A. Sarafidis,<sup>1</sup> Christodoulos E. Papadopoulos,<sup>2</sup> Aikaterini Papagianni,<sup>1</sup> and Carmine Zoccali<sup>3</sup>

**Table 2.** Overview of studies evaluating changes in LV diastolic function echocardiographic indices during hemodialysis and association with intradialytic volume changes

Author	Year	N	Time of Evaluation	Main Finding	Diastolic Function Change	Association between Changes in Indices and Volume	Volume Marker
Drighil et al. <sup>30</sup>	2008	17	Before and after hemodialysis	LV E and E/A ratio, and RVE decrease	Deterioration	Yes (+)	Intradialytic weight loss
Sadler et al. <sup>31</sup>	1992	24	Before, at 2 h, and after hemodialysis	LV and RV E and E/A ratio decrease	Deterioration	Yes (+)	Intradialytic weight loss
Dubin et al. <sup>32</sup>	2014	35	Before and during the last hour of hemodialysis	LV E/Em ratio decrease	Deterioration	Yes (+)	NT-proBNP
Fijalkowski et al. <sup>33</sup>	2006	25	Before and after hemodialysis	LV E and E/Em decrease	Deterioration	Yes (+)	Intradialytic weight loss
Graham et al. <sup>35</sup>	2003	17	Before and after hemodialysis	LV E and E/A ratio decrease	Deterioration	No	Intradialytic weight loss
Assa et al. <sup>36</sup>	2013	109	Before, at 60 and 180 intradialytic minutes, and after hemodialysis	LV E and Em decrease	Deterioration	No	BNP
Sarafidis et al. <sup>29</sup>	2016	41	Before and after two separate hemodialysis sessions	LV and RV E decrease	Deterioration	Yes (+)	Intradialytic weight loss

Studies are presented in chronologic order ("+" is used to present a positive correlation). E and Em, early non-tissue-Doppler and tissue-Doppler diastolic velocities (accordingly); A, late diastolic velocity; NT-proBNP, N-terminal pro b-type natriuretic peptide; BNP, brain natriuretic peptide.



**Figure 2.** Changes in echocardiographic indices of LV and RV remodeling and function during the 3-day and 2-day interdialytic intervals. Interdialytic changes in stroke volume (SV) and LVMi were similar, but interdialytic changes in left atrial volume index (LAVi), right atrial volume index (RAVi), tricuspid regurgitation peak gradient (PGr TVR), and RVSP were greater during the 3-day compared with the 2-day interval, suggesting increased pulmonary circulation and right ventricle loading over the 3-day period. (Illustration based on results from Tsilonis et al.<sup>47</sup>)



# Haemodialysis acutely deteriorates left and right diastolic function and myocardial performance: an effect related to high ultrafiltration volumes?

Pantelis A. Sarafidis<sup>1</sup>, Vasilios Kamperidis<sup>2</sup>, Charalampos Loutradis<sup>1</sup>, Konstantinos Tsilonis<sup>2</sup>, Fani Mpoutsouki<sup>2</sup>, Athanasios Saratzis<sup>3</sup>, Georgios Giannakoulas<sup>2</sup>, Georgios Sianos<sup>2</sup> and Haralambos Karvounis<sup>2</sup>

**Table 2. Comparisons between pre- and post-haemodialysis body weight, BP, HR and LV echocardiographic indices on the first and a standard weekly haemodialysis session**

Parameter	First weekly haemodialysis session (Monday or Tuesday)			Standard haemodialysis session (Wednesday/Thursday or Friday/Saturday)		
	Start	End	P-value	Start	End	P-value
Body weight (kg)	72.2 ± 12.5	69.3 ± 12.5	< 0.001	71.7 ± 12.5	69.0 ± 12.6	<0.001
SBP (mmHg)	145.5 ± 21.6	135.9 ± 23.5	0.009	143.1 ± 19.8	135.1 ± 19.6	0.022
DBP (mmHg)	77.9 ± 13.4	76.8 ± 11.2	0.547	78.2 ± 11.2	76.1 ± 13.1	0.224
HR (bpm)	70.1 ± 10.9	73.6 ± 13.5	0.004	69.0 ± 10.3	75.2 ± 11.9	<0.001
LVMi (g/m <sup>2</sup> )	139.2 ± 66.2	121.2 ± 62.7	< 0.001	139.6 ± 63.4	127.7 ± 66.7	0.006
LAVi (mL/m <sup>2</sup> )	44.6 ± 16.0	35.7 ± 14.3	< 0.001	43.0 ± 16.4	36.8 ± 17.1	<0.001
LVESVi (mL/m <sup>2</sup> )	26.2 ± 12.9	24.1 ± 12.8	0.126	28.2 ± 13.3	25.8 ± 12.7	0.039
LVEDVi (mL/m <sup>2</sup> )	58.3 ± 19.9	54.8 ± 23.3	0.138	61.8 ± 20.6	58.3 ± 22.0	0.053
LVEF (%)	55.7 ± 12.4	56.2 ± 11.1	0.798	56.1 ± 10.7	56.2 ± 12.3	0.901
SV (mL)	80.4 ± 18.2	72.9 ± 26.8	0.083	83.2 ± 30.1	73.7 ± 21.1	0.022
CO (L/min)	5.68 ± 1.50	5.35 ± 2.18	0.308	5.71 ± 2.09	5.46 ± 1.44	0.388
S <sub>mean</sub> LV (m/s)	0.077 ± 0.017	0.080 ± 0.020	0.324	0.074 ± 0.015	0.077 ± 0.016	0.153
LVOT (cm)	1.98 ± 0.24	1.97 ± 0.25	0.561	1.97 ± 0.23	1.98 ± 0.21	0.743
LVOT VTI (cm)	26.6 ± 5.9	24.1 ± 7.2	0.036	27.3 ± 8.6	24.1 ± 5.9	0.010
E wave (m/s)	0.96 ± 0.28	0.75 ± 0.27	< 0.001	0.89 ± 0.24	0.78 ± 0.29	<0.001
E/A	1.17 ± 0.44	0.94 ± 0.46	0.001	1.14 ± 0.49	0.92 ± 0.42	<0.001
DT (ms)	232.13 ± 62.87	242.99 ± 63.27	0.281	224.73 ± 53.28	225.02 ± 53.41	0.972
E <sub>mean</sub> wave (m/s)	0.19 ± 0.03	0.17 ± 0.03	<0.001	0.19 ± 0.04	0.18 ± 0.05	0.336
E/E <sub>mean</sub>	5.11 ± 1.42	4.60 ± 1.64	0.025	4.95 ± 1.76	4.56 ± 2.05	0.056
IVRT <sub>mean</sub>	0.076 ± 0.019	0.079 ± 0.024	0.355	0.076 ± 0.020	0.077 ± 0.023	0.668
TEI <sub>mean</sub>	0.50 ± 0.14	0.55 ± 0.17	0.021	0.52 ± 0.23	0.56 ± 0.16	0.399

**Table 4. Univariate and multivariate linear regression analyses of parameters possibly affecting the change in E index, reflecting LV diastolic function, during a standard haemodialysis session**

Parameter	Univariate analysis				Multivariate analysis			
	Estimate	SEM	95% CI	P-value	Estimate	SEM	95% CI	P-value
Age (per year increase)	0.004	0.001	0.001–0.006	0.003	0.003	0.001	0.001–0.005	0.023
Sex (female versus male)	0.009	0.040	–0.072–0.090	0.824				
IDWL (per L increase)	0.046	0.013	0.019–0.073	0.001	0.042	0.012	0.018–0.066	0.001
SBP change (per mmHg increase)	0.001	0.001	–0.002–0.001	0.684				
HR change (per bpm increase)	–0.004	0.003	–0.009–0.002	0.166	–0.003	0.002	–0.007–0.001	0.119
LVMi change (per g/m <sup>2</sup> increase)	0.001	0.001	–0.002–0.002	0.891				
CO change (per L/min increase)	0.014	0.011	–0.009–0.037	0.236				
TEI <sub>mean</sub> change (per unit increase)	–0.122	0.081	–0.286–0.042	0.140	–0.067	0.066	–0.202–0.069	0.323



# Haemodialysis acutely deteriorates left and right diastolic function and myocardial performance: an effect related to high ultrafiltration volumes?

Pantelis A. Sarafidis<sup>1</sup>, Vasilios Kamperidis<sup>2</sup>, Charalampos Loutradis<sup>1</sup>, Konstantinos Tsilonis<sup>2</sup>, Fani Mpoutsouki<sup>2</sup>, Athanasios Saratzis<sup>3</sup>, Georgios Giannakoulas<sup>2</sup>, Georgios Sianos<sup>2</sup> and Haralambos Karvounis<sup>2</sup>

**Table 3. Comparisons between pre- and post-haemodialysis values of RV echocardiographic indices and IVC diameter on the first and a standard weekly haemodialysis session**

Parameter	First weekly haemodialysis session (Monday or Tuesday)			Standard haemodialysis session (Wednesday/Thursday or Friday/Saturday)		
	Start	End	P-value	Start	End	P-value
RAV (mL)	27.30 ± 10.58	21.34 ± 10.05	<0.001	26.05 ± 13.46	22.54 ± 12.21	<0.001
RVEDD (cm)	3.61 ± 0.87	3.12 ± 0.75	<0.001	3.49 ± 0.75	3.18 ± 0.69	<0.001
IVC diameter (cm)	1.93 ± 0.41	1.54 ± 0.45	<0.001	1.79 ± 0.39	1.37 ± 0.40	<0.001
RAP (mmHg)	9.76 ± 3.82	7.88 ± 4.34	<0.001	9.32 ± 3.96	6.24 ± 4.10	<0.001
RVSP (mmHg)	44.64 ± 16.25	33.14 ± 12.43	<0.001	37.87 ± 13.74	30.16 ± 12.78	<0.001
RVOT VTI (cm)	19.97 ± 3.44	18.24 ± 4.72	0.006	19.61 ± 4.92	17.67 ± 4.19	0.006
TRV max (m/s)	2.87 ± 0.54	2.54 ± 0.54	<0.001	2.68 ± 0.55	2.46 ± 0.54	<0.001
S' RV (m/s)	0.15 ± 0.04	0.15 ± 0.04	0.575	0.14 ± 0.03	0.15 ± 0.04	0.149
PVR (dyn s/cm <sup>5</sup> )	1.63 ± 0.37	1.72 ± 1.02	0.541	1.59 ± 0.40	1.60 ± 0.37	0.806
E RV wave (m/s)	0.89 ± 0.26	0.67 ± 0.25	<0.001	0.86 ± 0.24	0.77 ± 0.31	<0.001
E' RV wave (m/s)	0.123 ± 0.042	0.113 ± 0.038	0.183	0.117 ± 0.036	0.110 ± 0.042	0.313
E'/A' RV	0.94 ± 0.67	0.80 ± 0.49	0.069	0.94 ± 0.67	0.75 ± 0.46	0.028
E/E' RV	8.55 ± 3.28	7.10 ± 2.54	0.008	7.97 ± 2.19	7.45 ± 2.88	0.308
TEI RV	0.52 ± 0.20	0.59 ± 0.20	0.021	0.50 ± 0.14	0.52 ± 0.17	0.145



**Table 5. Univariate and multivariate linear regression analyses of parameters possibly affecting the change in E RV index, reflecting RV diastolic function, during a standard haemodialysis session**

Parameter	Univariate analysis				Multivariate analysis			
	Estimate	SEM	95% CI	P-value	Estimate	SEM	95% CI	P-value
Age (per year increase)	0.003	0.002	0.001–0.006	0.095	0.001	0.001	–0.001–0.004	0.286
Sex (female versus male)	0.009	0.048	–0.089–0.107	0.850				
IDWL (per L increase)	0.080	0.013	0.053–0.106	<0.001	0.084	0.013	0.057–0.110	<0.001
SBP change (per mmHg increase)	0.002	0.001	–0.001–0.004	0.153	0.001	0.001	–0.001–0.003	0.199
HR change (per bpm increase)	–0.008	0.003	–0.014––0.002	0.013	–0.006	0.002	–0.010––0.001	0.018
RVEDD change (per cm increase)	–0.009	0.069	–0.150–0.131	0.896				
RAP change (per mmHg increase)	0.007	0.006	–0.006–0.020	0.292				
TEI RV change (per unit increase)	–0.239	0.138	–0.519–0.040	0.091	–0.052	0.095	–0.246–0.142	0.588



### Echocardiographic Parameters During Long and Short Interdialytic Intervals in Hemodialysis Patients

Konstantinos Tsilonis, MD,<sup>1</sup> Pantelis A. Sarafidis, MD, MSc, PhD,<sup>2,3</sup>  
 Vasilios Kamperidis, MD, MSc, PhD,<sup>1</sup> Charalampos Loutradis, MD, MSc,<sup>2</sup>  
 Panagiotis I. Georgianos, MD, PhD,<sup>3</sup> Konstantinos Imprialos, MD,<sup>2</sup>  
 Antonios Ziakas, MD, PhD,<sup>1</sup> Georgios Sianos, MD, PhD,<sup>1</sup> Pavlos Nikolaidis, MD, PhD,<sup>3</sup>  
 Anastasios N. Lasaridis, MD, PhD,<sup>3</sup> and Haralambos Karvounis, MD, PhD<sup>1</sup>



**Table 4.** Univariate and Multivariate Linear Regression Analysis of Parameters Possibly Affecting the Change in RVSP During Interdialytic Intervals

Parameter	Univariate Analysis		Multivariate Analysis	
	Estimate ± SE (95% CI)	P	Estimate ± SE (95% CI)	P
IDWG	1.512 ± 0.707 (0.104 to 2.920)	0.04	1.645 ± 0.659 (0.332 to 2.958)	0.02
SBP change	0.171 ± 0.144 (-0.114 to 0.457)	0.2		
Heart rate change	-0.028 ± 0.128 (-0.283 to 0.227)	0.8		
Sm RV change	-2.246 ± 26.880 (-55.740 to 51.248)	0.9		
E/Em RV change	0.820 ± 0.419 (-0.012 to 1.653)	0.05	1.142 ± 0.426 (0.293 to 1.990)	0.009
PVR change	6.177 ± 2.786 (0.633 to 11.721)	0.03	7.034 ± 2.644 (1.766 to 12.303)	0.01




# Changes in right ventricular dimensions, function, and pulmonary circulation loading according to the degree of interdialytic weight gain in maintenance hemodialysis patients

Vasileios Anastasiou<sup>1</sup> | Marieta P. Theodorakopoulou<sup>2</sup> |  
 Vasileios Kamperidis<sup>1</sup> | Stylianos Daios<sup>1</sup> | Konstantinos Tsilonis<sup>1</sup> |  
 Maria-Eleni Alexandrou<sup>2</sup> | Dimitrios V. Moysidis<sup>1</sup> | Afroditi Boutou<sup>3</sup> |  
 George Giannakoulas<sup>1</sup> | Antonios Ziakas<sup>1</sup> | Pantelis Sarafidis<sup>2</sup>

TABLE 2 Comparison of the echocardiographic indices of right ventricular performance and volume status at the start and end of the 3-d Interdialytic Interval depending on the IDWG corrected for dry weight.

Parameters	IDWG>4.5% (n = 21)			IDWG <4.5% (n = 20)			Net changes of high vs. low IDWG% groups		
	3-day start	3-day end	p-value	3-day start	3-day end	p-value	>4.5%	<4.5%	p-value
RV Sm (cm/s)	14 ± 3.31	15.21 ± 3.91	0.197	14.35 ± 3.77	14.65 ± 4.83	0.77	1.21 ± 3.9	0.3 ± 4.5	0.49
RVOT VTI	17.2 ± 3.54	20.34 ± 3.38	<0.001	18.34 ± 4.72	20.34 ± 2.62	0.042	3.14 ± 2.65	1.99 ± 3.96	0.45
RV Tei index	0.48 (0.43–0.66)	0.50 (0.36–0.67)	0.594	0.53 (0.43–0.76)	0.52 (0.35–0.62)	0.13	-0.2 (-0.12–0.12)	-0.06 (-0.17–0.04)	0.13
RV E/Em	6.93 ± 2.54	8.46 ± 3.39	<0.001	7.16 ± 2.1	8.85 ± 3.33	0.028	1.53 ± 1.40	1.69 ± 3.07	0.84
TR Vmax (m/s)	2.26 ± 0.42	2.83 ± 0.49	<0.001	2.56 ± 0.57	2.78 ± 0.59	0.013	0.57 ± 0.33	0.30 ± 0.50	0.15
PGr TRV (mm Hg)	21.15 ± 8.38	33.17 ± 11	<0.001	27.52 ± 12.5	33.72 ± 14.6	0.026	12.02 ± 7.57	6.19 ± 11.43	0.11
RVSP (mm Hg)	26.43 ± 11.17	42.86 ± 11.9	<0.001	32.52 ± 13.7	46.63 ± 19.2	<0.001	16.43 ± 5.37	14.11 ± 13.38	0.015
PVR (dyn*s*cm <sup>-5</sup> )	1.44 (1.25–1.72)	1.53 (1.36–1.77)	0.59	1.49 (1.28–1.75)	1.51 (1.32–1.98)	0.9	0.05 (-0.13–0.18)	0.06 (-0.42–0.35)	0.036
RVEDD (mm)	3.28 ± 0.58	3.71 ± 0.66	<0.001	3.09 ± 0.73	3.33 ± 0.79	0.015	0.43 ± 0.47	0.24 ± 0.39	0.47
RAVi (mL/m <sup>2</sup> )	19.38 (15.97–30.77)	30.89 (20.63–35.00)	<0.001	17.47 (15.24–20.55)	24.97 (18.81–31.23)	<0.001	4.74 (3.23–13.50)	5.38 (1.28–11.51)	0.22
IVCd (cm)	1.29 ± 0.32	1.85 ± 0.4	<0.001	1.5 ± 0.46	2 ± 0.44	<0.001	0.55 ± 0.27	0.50 ± 0.39	0.29

## Interdialytic changes of RVSP







# Intradialytic Cardiac Magnetic Resonance Imaging to Assess Cardiovascular Responses in a Short-Term Trial of Hemodiafiltration and Hemodialysis

Charlotte Buchanan,\* Azharuddin Mohammed,<sup>†</sup> Eleanor Cox,\* Katrin Köhler,<sup>‡</sup> Bernard Canaud,<sup>‡</sup> Maarten W. Taal,<sup>†</sup> Nicholas M. Selby,<sup>†</sup> Susan Francis,\* and Chris W. McIntyre<sup>§||</sup>

## 1<sup>st</sup> CMR study intradialytic

### Circumferential strain

### GLS





# Troponin T for the Detection of Dialysis-Induced Myocardial Stunning in Hemodialysis Patients

Tobias Breidhardt, James O. Burton, Aghogho Odudu, Mohamed Tarek Eldehni, Helen J. Jefferies, and Christopher W. McIntyre

All Patients (n=70)      Patients Not Developing HD-Induced Stunning      Patients Developing HD-Induced Stunning





Table 2. Detection of hemodialysis-induced myocardial stunning in univariate and multivariable regression analyses

Predictor	Odds Ratio (95% CI)	P Value
<b>Univariate analysis</b>		
age	1.05 (1.01–1.09)	0.02
male sex	1.93 (0.64–5.76)	0.24
history of coronary artery disease	2.11 (0.71–6.31)	0.18
history of diabetes mellitus	4.38 (1.40–13.76)	0.01
history of arterial hypertension	1.38 (0.51–3.74)	0.53
left ventricular ejection fraction	0.98 (0.93–1.03)	0.42
dialysis vintage	0.99 (0.98–1.01)	0.57
interdialytic hypotension (per every additional episode)	1.97 (1.05–3.69)	0.04
ultrafiltration volume (for every additional liter)	2.54 (1.22–5.31)	0.01
troponin T (for every 0.1-ng/ ml increase)	16.38 (2.84–94.43)	0.01
troponin T level . 0.06 ng/ ml	10.96 (3.11–38.62)	0.01
<b>Multivariable analysis</b>		
age	1.05 (0.99–1.11)	0.08
history of diabetes mellitus	2.95 (0.59–14.53)	0.18
interdialytic hypotension (per every additional episode)	1.95 (0.80–4.80)	0.14
ultrafiltration volume (for every additional liter)	4.38 (1.01–18.24)	0.04
troponin T (for every 0.1-ng/ ml increase)	9.33 (1.63–53.43)	0.01




# High-sensitive troponin T increase after hemodialysis is associated with left ventricular global longitudinal strain and ultrafiltration rate


Serkan Ünlü<sup>1,2,3</sup>, Asife Şahinarslan<sup>1</sup>, Burak Sezenöz<sup>1</sup>, Orhan Mecit Uludağ<sup>3</sup>,  
Gökhan Gökalp<sup>1</sup>, Özden Seçkin<sup>1</sup>, Selim Turgay Arınsoy<sup>4</sup>,  
Özlem Gülbahar<sup>5</sup>, Nuri Bülent Boyacı<sup>1</sup>




**Figure 1.** High-sensitive cardiac troponin T (hs-cTnT) levels before and after hemodialysis (HD). Comparison between mean values before and after HD is presented. Significance is indicated on the graph.



**Figure 2.** Comparison between relative change of high-sensitive cardiac troponin T (hs-cTnT) (y-axis) and the ultrafiltration rate (x-axis). The correlation coefficient (R) is indicated. P value is < 0.001.



**Figure 3.** Comparison between relative change of global longitudinal strain (GLS) measurements (y-axis) and relative change in high-sensitive cardiac troponin T (hs-cTnT) (x-axis). The correlation coefficient (R) is indicated. P value is < 0.001.



**Figure 4.** Comparison between relative change of global longitudinal strain (GLS) measurements (y-axis) and the ultrafiltrated volume (x-axis). The correlation coefficient (R) is indicated. P value is < 0.001.



# Hemodialysis-Induced Regional Left Ventricular Systolic Dysfunction and Inflammation: A Cross-sectional Study


Solmaz Assa, MD,<sup>1</sup> Yoran M. Hummel, BSc,<sup>2</sup> Adriaan A. Voors, MD, PhD,<sup>2</sup> Johanna Kuipers,<sup>3</sup> Ralf Westerhuis, MD, PhD,<sup>1,3</sup> Henk Groen, MD, PhD,<sup>4</sup> Stephan J.L. Bakker, MD, PhD,<sup>1</sup> Anneke C. Muller Kobold, PhD,<sup>5</sup> Wim van Oeveren, PhD,<sup>6,7</sup> Joachim Struck, PhD,<sup>8</sup> Paul E. de Jong, MD, PhD,<sup>1</sup> and Casper F.M. Franssen, MD, PhD<sup>1</sup>

**All Patients (N = 105)**      **No HD-Induced Regional LVSD (n = 76)**      **HD-Induced Regional LVSD (n = 29)**


**Table 3.** Regression Models for the Relationship Between Predialysis Concentration of Markers and Hemodialysis-Induced Regional LV Systolic Dysfunction

	Univariate		Multivariate <sup>a</sup>	
	OR (95% CI)	P	OR (95% CI)	P
<b>Inflammatory markers</b>				
Log(hs-CRP)	2.82 (1.10-7.25)	0.03	3.38 (1.02-11.20)	0.05
Log(PTX3)	6.27 (1.08-36.47)	0.04	2.41 (0.28-21.00)	0.4
Log(TNF- $\alpha$ )	0.72 (0.05-10.92)	0.8	1.18 (0.05-30.15)	0.9
Log(IL-6)	3.30 (0.86-12.70)	0.08	2.13 (0.44-10.31)	0.4
Log(IL-10)	0.34 (0.10-1.16)	0.09	0.21 (0.04-0.97)	0.05
Log(IL-6:IL-10 ratio)	4.14 (1.42-12.03)	0.009	3.92 (1.20-12.75)	0.02
<b>Bioincompatibility markers</b>				
Leukocytes	1.03 (0.83-1.27)	0.8	1.06 (0.85-1.33)	0.6
Neutrophils	1.03 (0.76-1.41)	0.8	1.05 (0.76-1.46)	0.8
Myeloperoxidase	0.08 (0.003-2.02)	0.1	0.28 (0.01-15.41)	0.5
Complement C3	4.15 (0.65-26.74)	0.1	8.26 (0.85-79.99)	0.07
<b>Endothelial markers</b>				
sICAM-1	0.53 (0.04-7.56)	0.6	0.44 (0.01-15.0)	0.7
vWF	1.01 (0.99-1.01)	0.08	1.01 (0.99-1.02)	0.4
Proendothelin	0.73 (0.01-46.1)	0.9	0.22 (0.001-36.25)	0.6
Endothelin 1	0.33 (0.10-1.11)	0.07	0.28 (0.06-1.27)	0.1

hcCRP



IL6 / IL10 ratio






Figure 1 Algorithm for evaluating and managing symptomatic cardiac dysfunction in hemodialysis patients.

# Sudden Cardiac Death Among Hemodialysis Patients

Melissa S. Makar, MD,<sup>1,2</sup> and Patrick H. Pun, MD, MHS<sup>1,2</sup>



Α Καρδιολογική Κλινική ΑΧΕΠΑ

**Table 1.** Possible Strategies for SCD Prevention in HD Patients

General Strategy	Specific Intervention
Manage cardiomyopathy Systolic dysfunction Diastolic dysfunction/LVH	Use carvedilol in patients with dilated cardiomyopathy Consider more frequent HD to reduce left ventricular mass; consider use of spironolactone, ACE inhibitors, or ARBs
Minimize arrhythmic triggers Potassium shifts	Monitor predialysis potassium frequently, especially after hospitalization, and change dialysate bath accordingly; avoid low (<2 mEq/L) potassium baths; consider potassium modeling and potassium-binding agents to reduce interdialytic hyperkalemia
Calcium shifts	Avoid low (<2.5 mEq/L) calcium baths, especially with concurrent use of QT interval-prolonging medications
Metabolic alkalosis	Avoid high dialysate bicarbonate concentrations in alkalotic patients; account for all sources of base in dialysate, including acetate
Rapid ultrafiltration	Encourage patient adherence to salt and fluid restrictions; avoid sodium ramping and large dialysate/serum sodium gradients; extend dialysis time so that ultrafiltration rates do not exceed 10 mL/kg/h
Dialysis-induced myocardial ischemia	Lower dialysate temperature to 0.5°C-2°C below patient temperature to reduce intradialytic hypotension
Medications	Avoid QT interval-prolonging medications when possible and reconcile medication list regularly
Weigh risks and benefits of ICDs	Consider ICDs for secondary prevention; increase communication between nephrologists and cardiologists to consider risks and benefits of primary prevention ICDs; consider leadless defibrillators to reduce vascular and infectious risks
Improve response to cardiac arrest	Increase dialysis clinic staff awareness of cardiac arrest risk and readiness to provide basic life support; encourage awareness and CPR training among patients and families





Ά Καρδιολογική Κλινική ΑΧΕΠΑ

**ΕΥΧΑΡΙΣΤΩ**